Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FLT3-ITD mutations do not impact the outcome of patients allografted with partial T-cell depleted grafts for AML with normal cytogenetics in first complete remission.
Beauverd Y, Tsopra O, Roosnek E, Simon A, Grandjean AP, Tirefort Y, Dantin C, Masouridi-Levrat S, Chalandon Y. Beauverd Y, et al. Among authors: roosnek e. Hematol Oncol. 2017 Sep;35(3):392-394. doi: 10.1002/hon.2272. Epub 2015 Nov 13. Hematol Oncol. 2017. PMID: 26563907 No abstract available.
Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion.
Beauverd Y, Roosnek E, Tirefort Y, Nagy-Hulliger M, Bernimoulin M, Tsopra O, Ansari M, Dantin C, Casini A, Grandjean AP, Chigrinova E, Masouridi-Levrat S, Chalandon Y. Beauverd Y, et al. Among authors: roosnek e. Biol Blood Marrow Transplant. 2014 Sep;20(9):1322-8. doi: 10.1016/j.bbmt.2014.04.023. Epub 2014 Apr 24. Biol Blood Marrow Transplant. 2014. PMID: 24769318 Free article.
Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
Simonetta F, Masouridi-Levrat S, Beauverd Y, Tsopra O, Tirefort Y, Koutsi A, Stephan C, Polchlopek-Blasiak K, Pradier A, Dantin C, Ansari M, Roosnek E, Chalandon Y. Simonetta F, et al. Among authors: roosnek e. Leuk Lymphoma. 2018 Mar;59(3):590-600. doi: 10.1080/10428194.2017.1344844. Epub 2017 Jul 6. Leuk Lymphoma. 2018. PMID: 28679328
Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B. Chalandon Y, et al. Among authors: roosnek e. Biol Blood Marrow Transplant. 2006 Jan;12(1):102-10. doi: 10.1016/j.bbmt.2005.09.010. Biol Blood Marrow Transplant. 2006. PMID: 16399574 Free article. Clinical Trial.
151 results